Loading
A phase 2 trial of IBI363 in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
A Study of IBI363 in Subjects With Advanced Melanoma is a phase 2 interventional study registered as NCT06081920 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2023-10-19 and due to reach its primary completion in 2028-10-19. Interventions recorded: IBI363. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IBI363, Innovent Biologics, Melanoma.
Shares IBI363, Innovent Biologics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares IBI363, Innovent Biologics.
Shares IBI363, Innovent Biologics.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares IBI363, Innovent Biologics.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/